Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis as of May 2024

MARA Rating Company December 16, 2025

Ofev / nintedanib for treating progressive fibrosing interstitial lung diseases as of November 2021

MARA Rating Company December 16, 2025

Ofev / nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80 % predicted as of February 2023

MARA Rating Company December 16, 2025

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy as of February 2021

MARA Rating Company December 16, 2025

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer as of April 2022

MARA Rating Company December 16, 2025

Nirmatrelvir plus other therapies for treating COVID-19 as of May 2025

MARA Rating Company December 16, 2025

Nivolumab / opdivo for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease as of March 2021

MARA Rating Company December 16, 2025

Nivolumab / opdivo for treating unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy as of June 2021

MARA Rating Company December 16, 2025

Nivolumab / opdivo for advanced non-squamous non-small-cell lung cancer after chemotherapy as of July 2021

MARA Rating Company December 16, 2025

Nivolumab / ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency as of July 2021

MARA Rating Company December 16, 2025